The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

September 9, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Lupus Nephritis Therapies Compared
The safety and efficacy of tacrolimus, mycophenolate mofetil (MMF) and cyclophosphamide (CYC) were evaluated as induction therapy for lupus nephritis in a Bayesian meta-analysis of nine randomized controlled trials involving 972 patients.1,2 Eleven direct comparisons were completed, including three pair-wise comparisons. The 11 direct comparisons included two studies of MMF v. tacrolimus, two studies of CYC v. tacrolimus and seven studies of CYC v. MMF.

You Might Also Like
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
Also By This Author
  • Upadacitinib at the FDA

The number of patients achieving a complete or partial renal remission after six months of induction therapy defined the efficacy outcome. The number of patients experiencing a serious infection, defined as serious, major and severe, and sepsis, pneumonia or upper respiratory infection defined the safety outcome. A rank order of efficacy and safety was also generated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Tacrolimus demonstrated a significantly higher overall response rate than CYC. Tacrolimus was also more efficacious than MMF and was the most efficacious induction treatment for these patients with lupus nephritis. Tacrolimus also had a higher probability of decreasing serious infection risk. MMF had higher remission rates and a better safety profile compared with CYC as an induction treatment in these lupus nephritis patients. The rank order of most to least efficacious was tacrolimus, MMF and CYC.

FDA Releases Draft Guidance for Naming Biosimilars
On Aug. 27, the U.S. Food and Drug Administration (FDA) released draft guidance on the naming of biosimilar agents.3 The document, known as the Nonproprietary Naming of Biologic Products—Guidance for Industry, was distributed for comments and suggestions for 60 days and would designate separate and distinct, non-proprietary names for originator biologic products, related biological products and biosimilar products.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Under the FDA proposed guidance, all biological and biosimilar drugs would be labeled with a four-letter code to help prescribers differentiate them. According to the FDA, there is a need to clearly identify the difference between biosimilar products and their reference biologics for purposes of safety and interchangeability. For example, the original drug might be labeled “drug-cslm” and a biosimilar version could be labeled “drug-xyzr.” The codes would not have any particular meanings, but would help prescribers and pharmacists avoid accidentally switching patients between drugs.

The ACR praised the FDA for issuing the draft guidance that requires separate and distinct names for biosimilars and biologic therapies. This action will assist rheumatologists and other specialists in ensuring patients continue to receive breakthrough therapies that are clinically appropriate and effective, without compromising health or safety.4

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics & Biosimilars, cyclophosphamide, FDA, Food and Drug Administration, Labeling Changes, Lupus nephritis, mycophenolate mofetil, tacrolimus

You Might Also Like:
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.